Sun Pharma to acquire Organon at $14.00 a share; EV $11.75 billion
Sun Pharmaceutical Industries · Pharmaceuticals & Biotechnology
Key highlights
- Sun Pharma will acquire 100% of Organon's outstanding shares for cash at US$ 14.00 per share, approximately US$ 3.99 Billion in total equity value
- Organon's enterprise valuation is approximately US$ 11.75 Billion; closing is expected in early 2027, subject to regulatory and Organon stockholder approvals
- Organon, incorporated in 2020 and spun off from Merck in June 2021, reported turnover of US$ 6,262 Mn (2023), 6,403 Mn (2024) and 6,215 Mn (2025) and has presence in 140 countries
Why it's rated major development: amount is ₹10,000 crore or more
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sun Pharmaceutical Industries
- Financial resultsMajor development· Adverse for the businessSun Pharmaceutical announces Q2 & H1 FY27 results and files Limited Review Reports
- Fundraise / allotmentNotableSun Pharma completes allotment of ₹7,816 crore NCDs via private placement
- Fundraise / allotmentNotableSun Pharma board approves NCDs up to ₹10,000 crore; independent director Doshi resigns
- Fundraise / allotmentNotableSun Pharma board to meet on 12 Oct 2026 to approve NCD issuance up to ₹15,000 Cr
- Acquisition / mergerNotableSun Pharma announces Organon shareholder approval for acquisition
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.